MEA115661: A multi-centre, open-label, long-term safety study of mepolizumab in asthmatic subjects who participated in the MEA115588 or MEA115575 trials

Trial Profile

MEA115661: A multi-centre, open-label, long-term safety study of mepolizumab in asthmatic subjects who participated in the MEA115588 or MEA115575 trials

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Aug 2017

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Registrational
  • Acronyms COSMOS
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 20 Aug 2016 Results published in the Clinical Therapeutics
    • 07 Mar 2016 Results of a subgroup post-hoc analysis(n=126) presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 07 Mar 2016 Results presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top